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Background: In fair-skinned Caucasian populations both the incidence and mortality rates
of cutaneous melanoma have been increasing over the past decades. With adjuvant therapies
still being under investigation, early detection is the only way to improve melanoma patient
survival. The inﬂuence of incisional biopsies on melanoma patient survival has been discussed
for many years. This study investigates both the inﬂuence of diagnostic biopsy type and the
presence of residual tumor cells in the re-excision specimen on disease free and overall survival.
Methods: After (partial) removal of a pigmented skin lesion 471 patients were diagnosed
with stage I/II melanoma and underwent re-excision and a sentinel node biopsy. All patients
were followed prospectively, mean follow up >5 years. Patients were divided according to
their diagnostic biopsy type (wide excision biopsy, narrow excision biopsy, excision biopsy
with positive margins and incisional biopsy) and the presence of residual tumor cells in their
re-excision specimen. Survival analysis was done using Coxs proportional hazard model
adjusted for eight important confounders of melanoma patient survival.
Results: The diagnostic biopsy was wide in 279 patients, narrow in 109 patients, 52 patients
underwent an excision biopsy with positive margins and 31 patients an incisional biopsy. In 41
patients residual tumor cells were present in the re-excision specimen. Both the diagnostic
biopsy type and the presence of tumor cells in the re-excision specimen did not inﬂuence
disease free and overall survival of melanoma patients.
Conclusions: Non-radical diagnostic biopsies do not negatively inﬂuence melanoma patient
survival.
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In fair-skinned Caucasian populations cutaneous
melanoma is an important growing public health
problem, causing a heavy burden on healthcare ser-
vices. Both its incidence and mortality rates have
been increasing in Europe over the past decades.
1
The absolute total number of new cases of melanoma
in the Netherlands is expected to be more than 4800
in 2015, compared with around 2400 in 2000.
2 The
Netherlands, as many other countries, has a two-
tiered medical care system in which patients need to
seek a medical opinion initially from a general
practitioner (GP) before referral if necessary, to a
specialist.
The mean number needed to treat (NNT), deﬁned
as the mean number of pigmented lesions needed to
be excised to identify one melanoma, among 468
GPs in Perth, Australia, was 29 and ranged from 83
in the youngest patients (£19 years) to 11 in the
oldest patients (‡70 years).
3 Assuming that for each
new case of melanoma another 20–50 patients with
pigmented skin lesions will visit the GP, the demand
for detection will increase quite markedly. With
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1424adjuvant therapies still being under investigation,
early detection is the only way to improve mela-
noma patient survival.
4 Dutch guidelines recom-
mend pigmented skin lesions suspect for melanoma
to be removed through a diagnostic excision biopsy
with a minimal lateral clearance of 2 mm.
5 This
recommendation is inline with the advice of the
National Institutes of Health (NIH) to remove any
suspicious lesion through excisional biopsy with a
narrow margin of normal-appearing skin.
6 The
inﬂuence of an incisional biopsy on melanoma pa-
tient survival has been discussed for many years and
different investigators have found contradicting re-
sults.
7–15 Two recent publications concluding inci-
sional biopsies not to interfere with melanoma
patient survival were not able to end this discussion
since patient groups were not fully comparable
16 or
follow up (FU) was short.
17
This study investigated both the inﬂuence of diag-
nostic biopsy type and the presence of residual tumor
cells in the re-excision specimen on melanoma patient
disease free survival (DFS) and overall survival (OS),
in 471 patients with a mean FU of more than 5 years.
Survival analysis was done using Coxs proportional
hazard model adjusted for; gender, age, site of pri-
mary melanoma, Breslow thickness, type of mela-
noma, ulceration, lymphatic invasion and sentinel
node (SN) status. Both the diagnostic biopsy type
and the presence of tumor cells in the re-excision




Between August 1993 and September 2004, 551
patients were diagnosed with clinical stage I/II cuta-
neous melanoma according to criteria of the Ameri-
can Joint Committee on Cancer (AJCC) and
underwent re-excision of the primary melanoma site
and a SN biopsy. If patients were referred to us from
another institution the pathologic characteristics of
the primary melanoma were reviewed in our hospital
before the SN procedure. All patients were treated
according to the same protocol; re-excision margins
were 1 cm for melanomas with a Breslow thickness
of £ 2 mm and 2 cm for melanomas with a Breslow
thickness of >2 mm. To identify and retrieve the SN,
the triple technique was used as described previ-
ously.
18–20 In short, the day before surgery patients
underwent a dynamic and static lymphoscintigraphy
to determine the lymphatic drainage pattern. Just
prior to surgery, Patent Blue V (Laboratoire Guerbet,
Aulnay-sous-Bois, France) was injected intradermally
next to the initial site of the melanoma. During sur-
gery, guided by a hand held gamma probe and the
blue staining of the draining tissues, the SN was re-
moved.
To investigate the inﬂuence on survival, patients
were divided both according to their diagnostic
biopsy type; wide excisional biopsy (lateral clear-
ance ‡ 2 mm), narrow excisional biopsy (lateral
clearance < 2 mm), excisional biopsy with positive
margins and incisional biopsy (includes punch) and
the presence of residual tumor cells in their re-exci-
sion specimen.
Statistical Analysis
Data were processed with the Statistical Package
for the Social Sciences software for Windows 2000
(SPSS 11.5, Chicago, IL). Coxs proportional hazard




Between August 1993 and September 2004, 551
patients were diagnosed with clinical stage I/II cuta-
neous melanoma, 257 male (46.6%) and 294 female
(53.4%) with a mean age of 49.9 years (Table 1). Most
primary melanomas were located on the trunk
(43.7%) or on the lower extremities (36.7%). Breslow
thickness was categorized into four groups ( £ 1.00
mm; 1.01–2.00 mm; 2.01–4.00 mm; >4.01 mm), but
due to spontaneous regression of the primary lesion
remained unknown in 38 patients. The majority of
patients had a superficial spreading melanoma
(65.0%) or a nodular melanoma (26.7%). In 46 pa-
tients the type of melanoma was different or re-
mained unknown (8.3%). Ulceration, defined as the
absence of intact epidermis overlying the major por-
tion of primary melanoma, was diagnosed in 80 pa-
tients (14.5%), unknown in 1 patient (0.2%) and
absent in 470 patients (85.3%). Lymphatic invasion
was present in 25 patients (4.5%), absent in 521 pa-
tients (94.6%) and remained unknown in 5 patients
(0.9%). The SN was negative in 446 patients (80.9%)
and positive in 94 patients (17.1%). In 11 patients the
SN was not removed and the SN status remained
unknown (2.0%). In total, there were 101 missing
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study.
SN Identiﬁcation
In 11 of the 551 patients the SN status remained
unknown (2.0%), in 5 of these patients the SN was
located in the deep lobe of the parotid gland and in
one patient the SN was located high in the left axilla,
in all cases the decision was made not to remove the
SN to avoid potential morbidity associated with the
intervention. The SN was not identiﬁed in 3 cases due
to non-visualization by preoperative lymphoscintig-
raphy. In one patient the SN was located in the right
axilla and could not be removed because the patient
was suﬀering from frozen shoulder syndrome, the
physical condition of another patient did not allow
further treatment. Therefore, the success rate of SN
identiﬁcation was 98% (540 of 551 patients). Two of
the patients with the SN located in the deep lobe of
the parotid gland experienced metastasis of the par-
otid gland, one patient is still alive with disease and
one patient is dead of disease. The patient whose
physical condition did not allow further treatment,
passed away soon after re-excision of the primary
melanoma site, from massive hematogenic and
lymphogenic metastasis. The 8 remaining patients
have shown no evidence of disease.
Diagnostic Biopsy Type and Survival
The inﬂuence of diagnostic biopsy type on DFS
and OS was tested in 471 patients with a mean FU of
more than 5 years; 279 patients (59.3%) underwent a
wide excision biopsy, 109 patients (23.1%) a narrow
excision biopsy, 52 patients (11.0%) an excision
biopsy with positive margins and 31 patients (6.6%)
an incision biopsy (Table 2A).
In 91/471 patients (19.3%) the SN was positive, 58/
279 patients (20.8%) after a wide excision biopsy, 14/
109 patients (12.8%) after a narrow excision biopsy,
15/52 patients (28.8%) after an excision biopsy with
positive margins and 4/31 patients (12.9%) after an
incisional biopsy.
In 79/471 patients (16.8%) a recurrence was found
during FU, 45/279 patients (16.1%) after a wide
excision biopsy (21 locoregional skin, 8 SN basin and
16 systemic), 17/109 patients (15.5%) after a narrow
excision biopsy (7 locoregional skin, 2 SN basin and 8
systemic), 10/52 patients (19.2%) after an excision
biopsy with positive margins (5 locoregional skin, 2
SN basin and 3 systemic) and 7/31 patients (22.6%)
after an incision biopsy (5 locoregional skin, and 2
systemic). But confounding factors were not equally
distributed between the diagnostic biopsy groups.
Therefore, survival analysis was done using Coxs
proportional hazard model adjusted for; gender, age,
site of primary melanoma, Breslow thickness, type of
melanoma, ulceration, lymphatic invasion and senti-
nel node (SN) status.
TABLE 1. Patient characteristics
Characteristics Patients (n = 551)
Follow up (years)





Mean (SD) 49.9 (15.3)
Site of primary melanoma
Lower extremity 202 (36.7%)




0<x£ 1 153 (27.8%)
1<x£ 2 207 (37.6%)
2<x£ 4 114 (20.7%)
> 4 39 (7.1%)
Unknown (regression) 38 (6.9%)
Type of melanoma















TABLE 2. Patient distribution according to (A) diagnostic






(years; mean ± SD)
Diagnostic biopsy type
Wide excision biopsy
( ‡ 2 mm)
279 (59.3%) 5.0 ± 3.0
Narrow excision
biopsy (0<x<2 mm)
109 (23.1%) 6.0 ± 2.7
Excision biopsy with
positive margins
52 (11.0%) 5.8 ± 2.9




(years; mean ± SD)
Re-excision specimen
No residual tumor cells 400 (90.7%) 5.1 ± 2.9
Residual tumor cells 41 (9.3%) 5.8 ± 2.6
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ness, type of melanoma, ulceration, lymphatic inva-
sion and SN status were all signiﬁcantly related to
both DFS and OS (Table 3). Site of primary mela-
noma on the head/neck was in univariate analysis
only signiﬁcantly related to DFS (Table 3). Diag-
nostic biopsy type did not have a signiﬁcant relation
with either DFS or OS (Table 3).
Even though, diagnostic biopsy type did not have a
signiﬁcant relation with either DFS or OS in univar-
iate Cox regression analysis it was also tested in
multivariate Cox regression analysis together with all
signiﬁcant variables from univariate analysis, to
investigate its inﬂuence on DFS and OS after correc-
tion for the confounding factors. In multivari-
ate analysis, the only signiﬁcant and independent
predictors of both DFS and OS were; age, Bre-
slow thickness, lymphatic invasion and SN status
(Table 3). Site of primary melanoma on the lower
extremities or head/neck and ulceration were in mul-
tivariate analysis only signiﬁcant and independent
predictors of DFS (Table 3). Also in multivariate
analysis, diagnostic biopsy type did not have a sig-
niﬁcant relation with either DFS or OS (Fig. 1A, B).
The same analysis was done after combining the
groups; the wide excision biopsy group was joined
with the narrow excision biopsy group and compared
to the excision biopsy group with positive margins
joined with the incision biopsy group. Still, diagnostic
biopsy type did not have a signiﬁcant inﬂuence on
either DFS or OS (data not shown).
Residual Tumor Cells in the Re-Excision Specimen
and Survival
441/471 Patients (93.6%) underwent re-excision of
the primary melanoma site and in 30 patients (6.4%)
the diagnostic biopsy was found to be suﬃcient. In
41/441 patients (9.3%) residual tumor cells were
found in the re-excision specimen (Table 2B). All 41
patients with residual tumor cells in the re-excision
specimen underwent either an excision biopsy with
positive margins or an incision biopsy. In none of
the patients with a wide or narrow excision biopsy
residual tumor cells were found.
In univariate analysis; gender, age, Breslow thick-
ness, type of melanoma, ulceration, lymphatic inva-
sion and SN status were all signiﬁcantly related to
both DFS and OS (Table 4). Site of primary mela-
noma on the lower extremity or head/neck was in
univariate analysis signiﬁcantly related to DFS and
site of primary melanoma on the head/neck or trunk
was signiﬁcantly related to OS (Table 4). Residual
tumor cells in the re-excision specimen did not have a
signiﬁcant relation with either DFS or OS (Table 4).
Even though, residual tumor cells in the re-excision
specimen did not have a signiﬁcant relation with ei-
ther DFS or OS in univariate Cox regression analysis
TABLE 3. Univariate and multivariate Cox regression analysis of disease-free survival and overall survival according to
diagnostic biopsy type





Tested variables P HR 95% CI PP HR 95% CI P
Diagnostic biopsy type
Wide excision biopsy 0.691 1.00 – 0.204 0.500 1.00 – 0.765
Narrow excision biopsy 0.360 0.71 0.39–1.28 0.255 0.315 0.74 0.37–1.51 0.411
Excision biopsy with positive margins 0.870 0.59 0.29–1.18 0.132 0.748 0.75 0.34–1.65 0.476
Incision biopsy 0.581 0.47 0.19–1.16 0.101 0.387 0.74 0.29–1.89 0.530
Gender 0.018 1.15 0.70–1.89 0.573 0.004 1.44 0.81–2.57 0.215
Age (years) 0.004 1.02 1.00–1.04 0.018 0.002 1.03 1.01–1.05 0.007
Site of primary melanoma
Lower extremity 0.091 1.00 – 0.023 0.153
Upper extremity 0.825 0.91 0.41–2.01 0.809 0.071
Head/Neck 0.014 3.40 1.45–7.97 0.005 0.095
Trunk 0.731 0.93 0.54–1.61 0.790 0.063
Breslow thickness (mm)
0<x£ 1 <0.001 1.00 – <0.001 <0.001 1.00 – 0.001
1<x£ 2 0.003 13.19 1.77–98.41 0.012 0.016 8.15 1.07–62.19 0.043
2<x£ 4 <0.001 34.11 4.50–258.60 0.001 <0.001 21.43 2.79–164.84 0.003
> 4 <0.001 15.73 1.86–132.81 0.011 <0.001 11.85 1.35–103.70 0.025
Type of melanoma <0.001 1.58 0.95–2.62 0.078 <0.001 1.57 0.88–2.79 0.128
Ulceration <0.001 1.83 1.09–3.07 0.023 <0.001 1.64 0.89–3.04 0.116
Lymphatic invasion <0.001 3.98 2.05–7.72 <0.001 <0.001 2.19 1.07–4.48 0.032
Sentinel node status <0.001 3.87 2.23–6.70 <0.001 <0.001 3.19 1.75–5.81 <0.001
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analysis together with all signiﬁcant variables from
univariate analysis, to investigate its inﬂuence on
DFS and OS after correction for the confounding
factors. In multivariate analysis, the only signiﬁcant
and independent predictors of both DFS and OS
were; age, site of primary melanoma on the head/
neck, Breslow thickness, lymphatic invasion and SN
status (Table 4). Also in multivariate analysis, resid-
ual tumor cells in the re-excision specimen did not
have a signiﬁcant relation with either DFS or OS
(Fig. 2A, B).
Consistent Confounders of Melanoma Patient Survival
Age, Breslow thickness, lymphatic invasion and
SN status were the most consistent, independent and
signiﬁcant confounders of melanoma patient DFS
and OS (Table 3, 4). Site of the primary melanoma
was not always an independent and signiﬁcant con-
founder of melanoma patient survival, but location
on the head/neck region consistently carried the
highest hazard ratio (HR) (Table 3, 4). Surprisingly,
ulceration was not an independent and signiﬁcant
confounder of OS (Table 3, 4).
DISCUSSION
Numerous investigators have studied the inﬂuence
of incisional biopsy on melanoma patient survival
and found contradicting results. Fitzpatrick et al.
found a ﬁve-year OS rate of 30% in the incisional
biopsy group as compared to 48% in the excisional
biopsy group but the diﬀerent biopsy groups were not
matched for important prognostic factors.
8 Epstein et
al. found a more favorable ten-year OS in the biopsy
group (65%) as compared to the primary wide exci-
sion group (56%) but biopsy was loosely deﬁned as
less than optimal or complete surgical excision.
9
Ironside et al. found a ﬁve-year OS rate of 66% in the
excision- and 43% in the incision biopsy group but
failed to describe the distribution of prognostic fac-
tors between both groups.
10 Rampen et al. also found
a worse prognosis for patients after an incision
biopsy (14 patients) but the study was small and
retrospective.
11 Grifﬁths et al. found no difference in
survival but 7/19 incisional biopsy patients were ex-
cluded because of missing histopathological data.
12
Survival rates were not signiﬁcantly different between
the incision- and excision biopsy groups of Lederman
et al., but patient groups were matched for Breslow
thickness only.
13 Lees et al. also indicated no signif-
icant averse effect of incisional biopsy in 96 patients,
but 40% of the histopathological data was not
assessable.
14 Austin et al did ﬁnd a signiﬁcantly re-
duced survival in the incisional biopsy group, but
patients in the incisional biopsy group were also
signiﬁcantly older.
15 The two most recent publica-
tions found no negative inﬂuence of incisional biop-
sies on melanoma patient survival but in Bong et al.
patients groups were not fully matched and in Martin
et al. median FU was only 28 months.
16,17
This study not only investigated the inﬂuence of
diagnostic biopsy type but also the presence of
residual tumor cells in the re-excision specimen on
melanoma patient survival in patient groups adjusted
for 8 important confounders of survival with a mean
FU > 5 years. Excision biopsies with positive mar-
gins and incisional biopsies were found not to inﬂu-
ence melanoma patient survival. Interestingly, DFS
and OS even seemed slightly better in the non-radical
biopsy groups (Fig. 1A, B). In line with this, patients
with residual tumor cells in their re-excision specimen
also had a slightly better survival as compared to
patients without residual tumor cells in their re-exci-
sion specimen (Fig. 2A, B). Melanoma is the most
immunogenic tumor identiﬁed to date; melanoma
speciﬁc T cells are detectable both in the blood and
in tumor draining lymph nodes from melanoma
patients and their frequency can be increased by
speciﬁc vaccination.
21–23 This intrinsic immunoge-
nicity makes melanoma lesions particularly amenable
to therapeutic approaches aimed at strengthening
FIG. 1. A Disease free survival rates and B overall survival rates
according to the initial biopsy type.
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combined with biopsy induced wound healing trigger
the melanoma patients immunesystem? In non-mel-
anoma skin cancer (NMSC) biopsy induced tumor
regression has previously been described, Swetter et
al reported that 24% of NMSCs transected on the
initial biopsy showed no residual tumor in the exci-
sion specimens and suggested biopsy induced wound
healing to play an important role.
24
Even though non-radical diagnostic biopsies and
residual tumor cells in the re-excision specimen do not
have a negative inﬂuence on melanoma patient sur-
vival, the routine use of incision biopsies is not rec-
ommended. Incisional biopsies often consist only of a
small percentage of the surface area of the pigmented
skin lesion making it diﬃcult to sample a represen-
tative area within the tumor. Somach et al found that
40% of the histopathological features were more
pronounced in the re-excision specimen as compared
to the incision biopsy and in 20% areas of invasive
melanoma not detected in the incisional biopsy were
observed in the re-excision specimen.
25 Further more
when melanoma is diagnosed, attempting to evaluate
the depth of invasion in an incisional biopsy is
treacherous and may lead to over- or underestimation
of the invasion.
26,27 Of course these problems are less
prominent in excision biopsies with positive margins,
here the majority of the lesion has been removed and
only the outer borders are compromised making a
sampling error highly unlikely.
In conclusion; age, Breslow thickness, lymphatic
invasion and SN status were the most consistent,
independent and signiﬁcant confounders of mela-
noma patient DFS and OS. The site of primary
melanoma and ulceration were also important con-
founders of survival. Both the diagnostic biopsy type
and the presence of residual tumor cells in the re-
excision specimen did not have a negative inﬂuence on
melanoma patient DFS and OS. With melanoma
incidence rates rising
1 and early detection of mela-
TABLE 4. Univariate and multivariate Cox regression analysis of disease-free survival and overall survival according to the
presence of residual tumor cells in the re-excision specimen





Tested variables P HR 95% CI PP HR 95% CI P
Residual tumor cells 0.094 0.79 0.38–1.64 0.532 0.230 0.83 0.36–1.92 0.668
Gender 0.025 1.14 0.68–1.92 0.611 0.009 1.22 0.65–2.28 0.531
Age (years) 0.007 1.02 1.00–1.04 0.038 0.007 1.02 1.00–1.04 0.040
Site of primary melanoma
Lower extremity 0.032 1.00 – 0.033 0.105 1.00 – 0.123
Upper extremity 0.830 0.95 0.41–2.20 0.910 0.069 2.21 0.85–5.71 0.102
Head/Neck 0.004 3.22 1.35–7.66 0.008 0.040 3.22 1.03–10.09 0.045
Trunk 0.647 0.96 0.54–1.74 0.903 0.049 2.02 0.98–4.20 0.059
Breslow thickness (mm)
0<x£ 1 <0.001 1.00 – <0.001 <0.001 1.00 – 0.004
1<x£ 2 0.005 12.82 1.71–96.07 0.013 0.020 7.99 1.04–61.49 0.046
2<x£ 4 <0.001 30.16 3.97–229.22 0.001 <0.001 20.13 2.59–156.25 0.004
> 4 <0.001 15.91 1.86–136.25 0.012 <0.001 11.84 1.32–106.54 0.028
Type of melanoma <0.001 1.61 0.95–2.73 0.076 <0.001 1.63 0.87–3.04 0.128
Ulceration <0.001 1.55 0.90–2.67 0.119 <0.001 1.61 0.85–3.05 0.141
Lymphatic invasion <0.001 4.16 2.13–8.14 <0.001 <0.001 2.24 1.04–4.80 0.038
Sentinel node status <0.001 3.30 1.87–5.83 <0.001 <0.001 3.05 1.56–5.96 0.001
FIG. 2. A Disease free survival rates and B overall survival rates
according to the presence of residual tumor cells in the re-excision
specimen.
DIAGNOSTIC BIOPSY AND MELANOMA PATIENT SURVIVAL 1429
Ann. Surg. Oncol. Vol. 14, No. 4, 2007noma still being the only way to improve melanoma
patient survival,
4 it is important for all physicians to
feel conﬁdent about removing a pigmented skin lesion
suspect for melanoma. Incisional biopsies are not
recommended but there is no cause for concern when
an excision biopsy turns out to have positive margins.
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